What is BWAY's current stock price?

BWAY (BrainsWay Ltd.) is currently trading at $15.93 with a market cap of $624.7M.

What sector is BrainsWay Ltd. in?

BrainsWay Ltd. (BWAY) operates in the Healthcare sector, specifically in the Medical - Devices industry.

Is BWAY a good stock to buy?

Analysts have a Buy consensus on BWAY with a price target of $15.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

BWAY BrainsWay Ltd.

Healthcare

$15.93+0.00%OpenMarket Cap: $624.7M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

71.36

PEG

0.44

P/B

8.08

P/S

10.62

EV/EBITDA

80.99

DCF Value

$-14.26

FCF Yield

1.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

75.5%

Operating Margin

10.1%

Net Margin

14.6%

ROE

12.3%

ROA

7.5%

ROIC

6.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$15.5M	$2.3M	$—
Q4 null	$14.5M	$2.9M	$—
FY null	$52.2M	$7.6M	$—
Q3 null	$13.5M	$1.6M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$15.00

Target (Median)

$15.00

Target Range

$15.00 - $15.00

0 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-03-12

HC Wainwright & Co.Buy

2026-01-26

HC Wainwright & Co.Buy

2025-12-08

Northland Capital MarketsOutperform

2025-11-12

HC Wainwright & Co.Buy

2025-08-25

Trading Activity

Insider Trades

View All

Mitrany Rayten Michal Etydirector

SellThu May 21

Mitrany Rayten Michal Etydirector

SellThu May 21

Mitrany Rayten Michal Etydirector

SellThu May 21

Mitrany Rayten Michal Etydirector

SellThu May 21

Zangen Abrahamdirector

SellWed Mar 18

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

Exchange

—

Beta

0.22

Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

Peers